# Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)

> **NCT06919848** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 74 (estimated)

## Conditions studied

- Biliary Tract Cancer (BTC)

## Interventions

- **DRUG:** TORIPALIMAB INJECTION(JS001 )
- **DRUG:** Lenvatinib
- **DRUG:** H101
- **DRUG:** FOLFOX

## Key facts

- **NCT ID:** NCT06919848
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06919848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06919848, "Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06919848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*